GlassScriptPhysician profile
Latonia Ward
NPI 1821028424
$5,955.91
in general payments reported to CMS, 2019-2025
33 companies · $896 in 2025
The $896 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $161 · 2021: $782 · 2022: $1,175 · 2023: $1,285 · 2024: $1,055 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,067 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,066.99 |
| Education | $169.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $859.15 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $644.27 | 2019-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $624.56 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $526.41 | 2021-2023 | Hetlioz, Fanapt |
| Lilly USA, LLC | $499.23 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $432.14 | 2021-2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $339.86 | 2022-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $265.75 | 2021-2023 | Varithena Administration Pack |
| Aurinia Pharma U.S., INC. | $250.00 | 2023-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $187.82 | 2019-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.10 | 2019-2025 | Jardiance |
| Fresenius USA Marketing, INC. | $128.50 | 2022-2023 | Velphoro, Korsuva |
| Calliditas Therapeutics US INC. | $124.82 | 2025 | Tarpeyo |
| Janssen Research & Development, LLC | $122.38 | 2024 | |
| Ardelyx, INC. | $115.51 | 2023-2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.35 | 2019-2025 | Otezla, Repatha |
| Mannkind Corporation | $93.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $73.49 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $51.54 | 2024-2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $50.20 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $44.27 | 2019 | |
| Vifor Pharma, INC. | $41.89 | 2019 | |
| Medtronic, INC. | $34.75 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.58 | 2021 | |
| Abbott Laboratories | $24.95 | 2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $23.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.19 | 2019 | |
| Corcept Therapeutics | $21.39 | 2025 | Korlym |
| Intra-Sana Laboratories | $20.90 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Arbor Pharmaceuticals, INC. | $18.66 | 2019 | |
| Akebia Therapeutics INC | $17.97 | 2024 | Auryxia |
| Pfizer INC. | $16.07 | 2019 | |
| Merck Sharp & Dohme LLC | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latonia Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.